Stockreport

Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

Navidea Biopharmaceuticals, Inc.  (NAVB) 
NASDAQ:AMEX Investor Relations: ir.navidea.com
PDF Data Demonstrated Quantitative Repeatability and Stability of SignalCompany Continues to Enroll Subjects as Planned to Complete the Phase 2B and Prepare for the Upcoming [Read more]